

> Stress testing (JACC 2012;60:1828; J Nucl Cardiol 2016; 23:606)


# NONINVASIVE EVALUATION OF CAD

### Stress testing (_JACC_ 2012;60:1828; _J Nucl Cardiol_ 2016; 23:606)

• **Indications:** dx obstructive CAD, evaluate ∆ in 臨床status in Pt with known CAD, risk stratify after ACS, evaluate exercise tolerance, localize ischemia (imaging required)

• **Contraindications** (_Circ_ 2002;106:1883; & 2012;126:2465)

**Absolute:** AMI within 48 h, high-risk UA, acute PE, severe sx AS, uncontrolled HF, uncontrolled arrhythmias, myopericarditis, acute aortic dissection

### Relative (discuss with stress lab): left main CAD, mod symptomatic valvular stenosis, severe HTN, HCMP, high-degree AVB, severe electrolyte 異常

### Exercise tolerance test (with ECG alone)

• Generally preferred if Pt can meaningfully exercise; ECG ∆s with Se ~65%, Sp ~80%

• Typically via treadmill with Bruce protocol (modified Bruce or submax if decond. or recent MI)

• Hold anti-isch. meds (eg, nitrates, βB) if dx’ing CAD but give to assess adequacy of meds

### Pharmacologic stress test (nb, requires imaging because ECG not interpretable)

• Use if unable to exercise, low exercise tolerance, or recent MI. Se & Sp ≈ exercise.

• Preferred if LBBB, WPW or V-paced, because higher prob of false ⊕ imaging with exercise

• _Coronary vasodilator:_ diffuse vasodilation → relative “coronary steal” from vessels with fixed epicardial dis. Reveals CAD, but _not_ if Pt _ischemic with exercise._ Regadenoson (↓ side effects), dipyridamole, adenosine. Side effects: flushing, ↓ HR, AVB, SOB, bronchospasm.

• _Chronotropes/inotropes_ (dobuta): more physiologic, but longer test; may precip arrhythmia

### Imaging for stress test

• Use if uninterpretable ECG (V-paced, LBBB, resting ST ↓ >1 mm, digoxin, LVH, WPW), after indeterminate ECG test, or if pharmacologic test

• Use when need to localize ischemia (often used if prior coronary revasc)

• **Radionuclide myocardial perfusion imaging** with images obtained at rest & with stress

### SPECT (eg, 99mTc-sestamibi): Se ~85%, Sp ~80%

### PET (rubidium-82): Se ~90%, Sp ~85%; requires pharmacologic stress, not exercise

ECG-gated imaging allows assessment of regional LV fxn (sign of ischemia/infarction)

• **Echo** (exercise or dobuta): Se ~85%, Sp ~85%; no radiation; operator dependent

• Cardiac MRI (with pharmacologic stress) another option with excellent Se & Sp

### Test results

• **HR** (must achieve ≥85% of max pred HR \[220-age\] for _exer._ test to be dx), **BP** response, peak **double product** (HR × BP; 正常 >20k), HR recovery (HRpeak – HR1 min later; 正常 >12)

• **Max exercise capacity** achieved (METS or min); **occurrence of symptoms**

• **ECG** ∆**s:** _downsloping_ or _horizontal_ ST ↓ (≥1 mm) 60–80 ms after QRS predictive of CAD (but does _not_ localize ischemic territory); however, STE highly predictive & localizes

• Duke treadmill score = exercise min – (5 × max ST dev) – (4 × angina index) \[0 none, 1 nonlimiting, 2 limiting\]; score ≥5 → <1% 1-y mort; –10 to + 4 → 2–3%; ≤–11 → ≥5%

• **Imaging:** radionuclide defects or echocardiographic regional wall motion abnormalities

reversible defect = ischemia; fixed defect = infarct; transient isch dilation → ? severe 3VD

false ⊕: breast → ant defect; diaphragm → inf defect. False ⊖: balanced (3VD) ischemia.

### High-risk test results (PPV ~50% for LM or 3VD, ∴ consider coronary angio)

• ECG: ST ↓ ≥2 mm _or_ ≥1 mm in stage 1 _or_ in ≥5 leads _or_ ≥5 min in recovery; ST ↑; VT

• Physiologic: ↓ or fail to ↑ BP, <4 METS, angina during exercise, Duke score ≤–11; ↓ EF

• Radionuclide: ≥1 lg or ≥2 mod. reversible defects, transient LV cavity dilation, ↑ lung uptake

### Myocardial viability (_Circ_ 2008;117:103; _Eur Heart J_ 2011;31:2984 & 2011;32:810)

• Goal: identify hibernating myocardium that could regain fxn after revascularization

• Options: **MRI** (Se ~85%, Sp ~75%), **PET** (Se ~90%, Sp ~65%), **dobutamine stress**

### echo (Se ~80%, Sp ~80%); **SPECT/rest-redistribution** (Se ~85%, Sp ~60%)

In 病人 with LV dysfxn, viabil. doesn’t predict ↑ CABG benefit vs. med Rx (_NEJM_ 2011;364:1617)

### Coronary CT/MR angio (_NEJM_ 2008;359:2324; _Circ_ 2010;121:2509; _Lancet_ 2012;379:453)

• 病人 with CP: CCTA 100% Se, 54% Sp for ACS, ∴ NPV 100%, PPV 17% (_JACC_ 2009;53:1642). ↓ LOS, but ↑ cath/PCI, radiation vs. fxnal study (_NEJM_ 2012;367:299; _JACC_ 2013;61:880).

• Sx outPt: CCTA vs. fxnal testing → ↑ radiation, cath/PCI early; by 5 y, ↓ CHD death/MI with similar rates of cath/PCI (_NEJM_ 2018;379:924)

• Unlike CCTA, MR does not require iodinated contrast or radiation, and can assess LV fxn

### Coronary artery calcium score (_NEJM_ 2012;366:294; _JAMA_ 2012;308:788)

• Quantifies extent of calcium; thus, _estimates_ plaque burden (but _not_ % coronary stenosis)

• CAC sensitive (91%) but not specific (49%) for presence of CAD; high NPV to 排除 CAD

• May provide incremental value to 臨床scores for risk stratification (_JAMA_ 2004;291:210). ACC/AHA guidelines note CAC assessment is reasonable in asx 病人 with intermed risk (7.5– <20% 10-y risk) and selected borderline risk (5– <7.5% 10-y risk) (_Circ_ 2019;139:e1082).
